Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC).

被引：0
|
作者：
Meyerhardt, JA
Xhu, A
Enzinger, PC
Ryan, DP
Clark, JW
Kulke, MH
Michelini, A
Vincitore, M
Thomas, A
Fuchs, CS
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3580
引用
收藏
页码：265S / 265S
页数：1
相关论文
共 50 条
  • [1] Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Meyerhardt, JA
    Zhu, AX
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Kulke, MH
    Earle, CC
    Vincitore, M
    Michelini, A
    Sheehan, S
    Fuchs, CS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1892 - 1897
  • [2] Phase II Trial of Erlotinib and Capecitabine for Patients with Previously Untreated Metastatic Colorectal Cancer
    Kozuch, Peter
    Malamud, Steve
    Wasserman, Carrie
    Homel, Peter
    Mirzoyev, Takhir
    Grossbard, Michael
    [J]. CLINICAL COLORECTAL CANCER, 2009, 8 (01) : 38 - 42
  • [3] A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer.
    Blaszkowsky, LS
    Kulke, KH
    Ryan, DP
    Clark, JW
    Meyerhardt, J
    Zhu, AX
    Lawrence, C
    Fuchs, CS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 332S - 332S
  • [4] Phase II study of capecitabine and gemcitabine in patients with metastatic colorectal cancer (mCRC)
    Iqbal, S.
    Yang, D.
    Cole, S.
    El-Khoueiry, A. B.
    Boswell, W.
    Agafitei, R.
    Lujan, R.
    Lenz, H. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353
    George, Thomas J.
    Ivey, Alison Marguerite
    Dang, Long H.
    Daily, Karen Colleen
    Hou, Wei
    Viviano, Dana Lynn
    Watson, Scott
    Granicz, Renee
    McEwan, Margaret A.
    Yan, Hui
    Allegra, Carmen Joseph
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [6] A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients
    Van Cutsem, E.
    Verslype, C.
    Beale, P.
    Clarke, S.
    Bugat, R.
    Rakhit, A.
    Fettner, S. H.
    Brennscheidt, U.
    Feyereislova, A.
    Feyereislova, A.
    Delord, J. -P.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (02) : 332 - 339
  • [7] Randomized phase ll study of oxaliplatin reintroduction and biweekly XELOX in previously treated patients with metastatic colorectal cancer (mCRC): ORION study
    Keiichiro, I.
    Ishibashi, K.
    Matsuda, C.
    Tamagawa, H.
    Munemoto, Y.
    Tanaka, C.
    Fukunaga, M.
    Tokunaga, Y.
    Oba, K.
    Sakamoto, J.
    Mishima, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S559 - S559
  • [8] A PHASE II STUDY OF CAPECITABINE, IRINOTECAN, AND BEVACIZUMAB (XELIRI-A) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Chen, E.
    Welch, S.
    Kryzanowska, M.
    Mackay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 36 - 37
  • [9] A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Chen, E. X.
    Welch, S.
    Krzyzanowska, M.
    MacKay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] A phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients.
    Delord, JP
    Beale, P
    Van Cutsem, E
    Clarke, S
    Verslype, C
    Bugat, R
    Rakhit, A
    Fettner, S
    Brennscheidt, U
    Feyereislova, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 266S - 266S
12345